The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Nisarg Vakharia - Lucky Investment Managers Private Limited - Analyst
: Sir, my question was that you had said that this large generic supply is for a finite period of time. Is this the last quarter for that supply or we still
have visibility going ahead?
Question: Nisarg Vakharia - Lucky Investment Managers Private Limited - Analyst
: So I think we were at a run rate of $380 million in the U.S. before this large generic supply. Is that the run rate that we should see going ahead?
Question: Nisarg Vakharia - Lucky Investment Managers Private Limited - Analyst
: Okay. Second question and last question is, sir, that by when should we expect a slightly better growth in the domestic formulation business? I
think 8% is much lower as per your standard of excellence.
without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks of Thomson Reuters and its
affiliated companies.
AUGUST 13, 2019 / 1:00PM, SUNPHARMA.NSE - Q1 2020 Sun Pharmaceutical Industries Ltd Earnings Call
Question: Nisarg Vakharia - Lucky Investment Managers Private Limited - Analyst
: Okay. But is this a new normal for large companies in the domestic formulation where 12% to 13% is the growth to expect? Or can we expect higher
growth in the near future?
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: Sir, in your press release, you mentioned one drug going into clinical this year. Is this related to additional indications for ILUMYA or is this a new
opportunity?
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: Okay, okay. And...
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: This is a new opportunity?
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: Understood. And my second -- okay. And my second question is on R&D. We mentioned that R&D was 15%. If I look at my generic spend, is it fair
to assume that generics spend is likely to remain similar year-on-year or even from this quarter and large part of increase would be led by specialty?
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: Understood. And last, on CEQUA, sir, any reason for why the drug is being delayed again? I think last quarter we had guided to a second quarter
launch, especially given the risk of generics RESTASIS?
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: So this is the key reason.
Question: Neha Manpuria - JP Morgan Chase & Co, Research Division - Analyst
: But sir, don't you think it could potentially impact the pricing strategy for CEQUA or you would think both those opportunities -- I mean CEQUA
would have a separate opportunity in the U.S. irrespective of the number of players in RESTASIS?
Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst
: Sir on ILUMYA, is there any decision on the initiation of the additional indication trials?
Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst
: And sir...
Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst
: And sir, what could be the duration for the study?
Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst
: And sir, while it's early days, typically in the IL-23 what's your experience been? Is psoriasis the primary indication, and these are add-on indications
or they are eventually going to develop as equally important indications or additional indications?
Question: Nitin Agarwal - IDFC Securities Limited, Research Division - Analyst
: Right. And sir, last one, on the ROW market there has been pretty strong growth in the quarter, you've mentioned combination of inorganic as well
| 
